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In July 2009, the German Standing Committee on 
Vaccination (STIKO) modified its recommendations for 
varicella and pertussis vaccination, based on newly 
available data on disease epidemiology, vaccine 
effectiveness (VE) and safety, and an evaluation of the 
feasibility of the recommended immunisation strat-
egy. The recommendation for varicella vaccine now 
includes a routine two-dose schedule with the admin-
istration of the first dose at the age of 11 to 14 months 
and the second dose at the age of 15 to 23 months, 
with a minimum interval of four weeks between these 
doses. Furthermore, STIKO recommended adding a 
one-time pertussis booster to the adult vaccination 
schedule to expand the cocoon strategy in place since 
2004. The recommendation of a booster vaccination 
with an acellular pertussis vaccine every 10 years for 
persons employed in the care of pre-school children 
and for healthcare personnel in paediatric, gynaeco-
logic and obstetric health facilities was extended to 
persons employed in schools and in other institutions 
caring for older children, and to all healthcare person-
nel. These recommendations were based on available 
epidemiological data showing an increase in incidence 
from 7-10 cases per 100,000 inhabitants in 2002-2004 
to over 30 by 2007. Moreover, the high burden of per-
tussis in infants at 94 hospitalised cases per 100,000 
infants in 2007 suggested that the previous cocoon 
strategy was insufficient.
Introduction
The German Standing Committee on Vaccination 
(STIKO) is a board of honorary experts in the fields of 
vaccinology, infectious disease epidemiology, micro-
biology and virology, paediatrics, evidence-based 
medicine and others. STIKO members are appointed 
by the Federal Ministry of Health every three years. 
STIKO reviews its recommendations for vaccination on 
an annual basis. Its decision-making process is based 
on published data on disease epidemiology, vaccine 
effectiveness (VE), and safety, and on the feasibility 
of the recommended immunisation strategy. STIKO is 
not responsible for a health economic assessment of 
the effect of vaccination. In this paper we communicate 
the major modifications to the immunisation schedule 
in Germany implemented in July 2009 and we detail 
the scientific rationale for the changes [1]. The main 
changes were the addition of a second dose of varicella 
vaccine to the routine childhood vaccination schedule 
and the recommendation of a single pertussis booster 
for adults.
So far, Germany is the only country in Europe to have 
introduced a nationwide recommendation for routine 
childhood varicella vaccination. Since the introduc-
tion of, initially, a one-dose varicella vaccination in 
children, a significant reduction of varicella cases in 
children was observed in a nationwide sentinel surveil-
lance system, as recently published by Siedler et al. 
[2]. This positive experience with varicella vaccination 
in Germany and the deliberations of the STIKO on the 
introduction of a two-dose varicella vaccination sched-
ule might be helpful for other countries in Europe in 
their decision making process. 
Second dose of varicella vaccine in children 
In 2004, STIKO recommended routine varicella vac-
cination for all children older than 11 months with the 
aim of reducing varicella associated morbidity and the 
reduction of the burden of disease [3]. A single dose 
of monovalent varicella vaccine was recommended at 
11 to 14 months of age and at that time, two licensed 
vaccines were available for this purpose in Germany, 
Varilrix and Varivax. In 2006, the measles-mumps-
rubella-varicella (MMRV) vaccine (Priorix-Tetra) was 
licensed for administration in two doses at least four 
weeks apart [4]. In 2008, the licensed immunisa-
tion schedule of both monovalent varicella vaccines 
changed to a two-dose scheme for all children [5,6].
Based on epidemiological data from Germany and 
the United States (US) as well as newly available 
data on varicella zoster virus (VZV) vaccine immuno-
genicity and effectiveness after one and two doses 
of VZV-containing vaccines, STIKO decided to follow 
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the change of vaccine licensures and recommended a 
routine two-dose vaccination strategy in children. The 
aim of this recommendation is to reduce the number of 
varicella outbreaks, the number of cases with varicella 
breakthrough illness (BI) and the transmission of VZV 
to susceptible persons with a higher risk for severe 
varicella disease such as pregnant women and immu-
nocompromised patients. 
Epidemiological data from 
Germany and the US
Varicella is not notifiable in Germany. Therefore, a 
country-wide sentinel project on varicella and zoster 
epidemiology was established in Germany in April 
2005 [7,8]. The constitution of the sentinel system and 
its first results covering the time frame April 2005 to 
March 2009 have been published recently [2]. Since 
sentinel surveillance cannot provide population-based 
data, varicella incidence and vaccination coverage 
cannot be calculated directly. However, from 2005 to 
2009, physicians reporting to the sentinel diagnosed 
successively fewer children with varicella with a signif-
icantly decreasing trend over time, while they adminis-
tered a rapidly increasing number of varicella vaccines 
for first doses and since 2008, second doses of VZV-
containing vaccine as well. A stable number of senti-
nel physicians reported around 60% fewer varicella 
cases in the 2008-9 season than in the 2005-6 sea-
son. Concurrently, a rising number of varicella BI was 
reported over the observation period [2,8]. 
Available information on vaccine coverage for the fed-
eral state of Schleswig-Holstein shows that coverage in 
children under 24 months of age with one dose of VZV 
containing vaccine, increased from 11% in 2006 to 83% 
in 2008 [personal communication Hans-Martin Bader 
and Maik Ludwig]. 
In 2008 and 2009, the RKI investigated seven varicella 
outbreaks in day-care centres including 631 children 
with available varicella vaccination information [9]. The 
attack rate was 13% in vaccinated children and 48% in 
unvaccinated children, resulting in an overall VE of 71% 
[95% confidence interval (CI): 57-81] in the multivari-
able analysis [9]. VE differed significantly by disease 
severity and number of doses administered. VE of one 
dose and two doses of VZV-containing vaccines was 
estimated to be 62% [95% CI: 43-75] and 94% [95% CI: 
75-98], respectively. Furthermore, results of outbreak 
investigations in Germany suggest that VE and the risk 
of varicella BI are not uniform for the different varicella 
vaccine products available in Germany [9]. 
The US varicella vaccination programme implemented 
in 1996 recommended one dose of monovalent vari-
cella vaccine at the age of 12 to 18 months and 
achieved over 90% reduction in varicella morbidity in 
children between 1995 and 2005 [10,11]. Since vari-
cella outbreaks continued to occur and an increasing 
number of cases with varicella BI was observed in 
active surveillance areas, the US Advisory Committee 
on Immunization Practices (ACIP) recommended a sec-
ond dose of varicella vaccine for all children aged four 
to six years in 2007 [12]. However, when applying these 
data to the German situation, it must be kept in mind 
that there is only one vaccine (Varivax) available in the 
US and a high vaccination coverage over 90% in chil-
dren under three years old has been achieved for a pro-
longed period of time [11].
Effectiveness, immunogenicity, and 
safety of VZV-containing vaccines 
VE after one dose Varivax was estimated at 84.5% 
(range: 44-100) in a recent review [13]. Estimates from 
three epidemiological studies on the VE of one dose 
of Varilrix range from 20 to 92% [14-16]. So far no 
data on VE after two doses of Priorix-Tetra have been 
published. 
In 2008, the licensed immunisation schedule of both 
monovalent varicella vaccines changed to a two-dose 
scheme for all children [5,6]. The regulatory authori-
ties based this change of licensure on immunogenicity 
data after one and two doses of VZV containing vac-
cines and on a large epidemiological study by Kuter 
et al. conducted in the US in the 1990s using Varivax, 
although at a higher potency than available licensed 
vaccines [17-19]. In this study the risk of developing 
varicella 42 days after vaccination was 3.3-fold lower in 
children who received two doses of Varivax compared 
with those who received only one dose (p<0.001). The 
estimated vaccine efficacy for the 10-year observa-
tion period for one or two doses Varivax was 94.4% 
and 98.3%, respectively (p<0.001). This efficacy esti-
mate was based on comparison with historical data of 
annual varicella incidences in unvaccinated suscepti-
ble children. In a randomised controlled trial in 10-21 
month-old VZV seronegative children an over 20-fold 
higher geometric mean titre (GMT) of VZV antibodies 
was observed in children with two doses of Priorix-
Tetra compared with children vaccinated with only one 
dose of a monovalent varicella vaccine [17]. However, 
the study by Kuter et al. showed that GMTs decreased 
to similar levels within several years regardless of the 
number of doses (one or two) applied [19]. Therefore, 
the reliability of VZV antibody levels as a correlate of 
protection after vaccination remains unclear. 
A good safety profile of VZV-containing vaccines avail-
able in Germany has been reported [4-6]. However, for 
the MMRV vaccine ProQuad, which is only available in 
the US, febrile seizures were observed more frequently 
post-vaccination than after simultaneous administra-
tion of MMR and monovalent varicella vaccines in chil-
dren under two years of age. [20]. 
Feasibility of routine two-dose 
varicella vaccination in children
The first dose of VZV-containing vaccine is recom-
mended at the age of 11 to 14 months and the second 
dose at the age of 15 to 24 months. Thus, varicella vac-
cination can be administered simultaneously with the 
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measles-mumps-rubella (MMR) vaccination using a 
monovalent varicella vaccine plus an MMR vaccine or 
using the licensed MMRV vaccine. However, varicella 
vaccination can be offered to any child aged 11 months 
or older. A second dose is also recommended for all 
children who thus far received only one dose of VZV-
containing vaccine. 
Pertussis vaccination of adults
In July 2009, STIKO recommended adding a single 
pertussis booster to the adult vaccination schedule 
against pertussis, in order to expand the cocoon strat-
egy which recommended pertussis vaccination for all 
adults with close contact to infants since 2004. The 
2004 recommendations also included a booster vacci-
nation with an acellular pertussis (ap) vaccine every 10 
years for persons employed in the care of pre-school 
children and for healthcare personnel in paediatric, 
gynaecologic and obstetric health facilities. These were 
expanded to include persons employed in schools and 
in other institutions caring for older children, as well 
as all healthcare personnel. The new recommendations 
were based on careful analysis of available epidemio-
logical data on the disease burden in adults as well 
as data on immunogenicity, effectiveness and safety 
of available vaccines. The aim of the updated recom-
mendations is to decrease pertussis-related morbidity 
in adults as well as in non-immune, unprotected con-
tacts, particularly infants [21;22]. 
Epidemiological data from Germany for adults
Pertussis is a notifiable disease in five of the 16 
German federal states. Despite increasing vaccina-
tion coverage among children at school entry to over 
93%, the incidence of pertussis in adults in the states 
with statutory surveillance increased from 7-10 cases 
per 100,000 inhabitants in 2002-2004 to a maximum 
of 32 in 2007, decreasing only slightly to 30 in 2008 
[22;23]. The average age of notified cases increased 
from 15 years in 1995 to 42 years in 2008, with a con-
comitant increase in the proportion of cases older than 
19 years (adult cases) from 20 to 75%. Sentinel sur-
veillance performed from 2000-2004 [24] estimated a 
similar annual incidence in an east and a west German 
city, 169 and 160 pertussis cases per 100,000 adult 
inhabitants, respectively, translating to a nationwide 
estimated incidence of 160. However, pertussis inci-
dence increased according to statutory surveillance in 
the years following conclusion of this sentinel study. 
These figures thus suggested a marked under-ascer-
tainment in the statutory surveillance system. In addi-
tion, the burden of pertussis in infants remains high 
with an incidence of 94 hospitalised cases per 100,000 
infants in 2007, implying that the cocoon strategy 
implemented in 2004 was insufficient.
The majority of pertussis outbreaks notified from 
2002-2007 in the five German federal states with statu-
tory pertussis surveillance involved children older than 
nine years (70% of cases in outbreaks with more than 
five cases), which was the rationale for expanding the 
recommendation for pertussis vaccination to persons 
employed in schools and other institutions involved in 
the care of older children. A Canadian study calculated 
that healthcare personnel had a 1.7-fold elevated risk 
for pertussis compared with the general population 
[25]. Numerous pertussis outbreaks among healthcare 
personnel involved in the care of adults have been 
published [26] and a modelling study in the United 
Kingdom estimated a high incidence of pertussis in 
hospitalised elderly patients [27].
Adults with pertussis often fail to present with the 
full-blown clinical picture, but nonetheless suffer sig-
nificant morbidity. In the above mentioned surveillance 
study by Riffelmann et al. [24], the median duration of 
the primary symptom, cough, was 48 days (maximum: 
72 weeks) and on average, patients consulted their 
general physician 5.4 times and 27% were referred 
to a specialist. Antibiotics were prescribed for 53% of 
patients and 13% received steroids. In various case 
series between 23% and 28% of all adult patients with 
pertussis suffered complications, including sinusitis, 
otitis media, incontinence, weight loss, rib fractures, 
syncope and pneumonia [24;25;28;29]. Hospitalisation 
was reported in 1 to 3% of adult pertussis cases 
[25;29-31]. 
Effectiveness, immunogenicity and 
safety of pertussis vaccines
Effectiveness of vaccination with an ap vaccine con-
taining three pertussis antigens was demonstrated 
in adults in one randomised controlled trial, which 
was, however, based on the observation of only 10 
pertussis cases in total: one case amongst 1,391 tet-
anus-diphtheria-acellular pertussis (Tdap)-vaccinated 
participants, and nine pertussis cases amongst 1,390 
hepatitis A vaccinated participants [34]. Vaccine effi-
cacy was estimated at 92% (95% CI 32-99). Numerous 
studies have demonstrated immunogenicity of pertus-
sis vaccines in adults equivalent to that observed in 
studies in children in which clinical efficacy was shown 
[32]. These studies have also demonstrated that the 
safety and reactogenicity of ap vaccines is similar to 
that of Td (tetanus-diphtheria) vaccines. 
Cost-effectiveness
Lee et al. [33] performed a cost-effectiveness analysis 
for vaccination of adults in Germany using conserva-
tive estimates of pertussis incidence and including 
direct costs as well as indirect costs due to loss of 
work by means of a Markov model. This suggested that 
one time vaccination of around 62% of adults would be 
cost-effective and possibly cost-saving, at a cost of 160 
Euros per pertussis case prevented. Two other models 
tailored to the US situation came to similar conclusions 
[21;34;35]. 
Feasibility of implementing a one-
time adult pertussis booster
Implementation of an adult booster is considered fea-
sible. Telephone surveys in Germany revealed a high 
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acceptance of tetanus vaccination, with 75% of a 
population based sample of adults reporting having 
received a tetanus-containing vaccination in the past 
10 years (unpublished data, RKI). However, it is essen-
tial that Tdap vaccines are made widely available for 
tetanus post-exposure immunisation in emergency set-
tings. In addition, efforts are needed to improve vac-




Germany is currently the only country in Europe that 
includes varicella vaccination in the routine immuni-
sation schedule for children. Results from sentinel 
surveillance show that the recommendation of rou-
tine varicella vaccination for all children older than 11 
months in 2004 has had a positive effect on the overall 
burden of varicella in Germany [2]. Based on immuno-
genicity data after one and two doses VZV-containing 
vaccines (indirect evidence) and based on the findings 
of the study of Kuter et al., licensures of both monova-
lent varicella vaccines changed to a two-dose schedule 
[17-19]. With respect to recent epidemiological findings 
in Germany and from the US, where varicella vaccines 
are included in the routine immunisation programmes 
since 1996 [2,11], STIKO decided to follow the change 
of licensure and recommended a second dose for all 
children in July 2009. As published VE estimates vary 
widely, and one VZV vaccine (ProQuad) has been asso-
ciated with an increased risk of febrile seizures in chil-
dren less than 2 years of age [13-16,20], there is a need 
for additional post-marketing data on safety and effec-
tiveness of VZV-containing vaccines. A population-
based VZV surveillance system should be established 
in Germany to evaluate the effect of routine varicella 
vaccination in children and to monitor varicella and 
herpes zoster incidences in all age groups.
Pertussis vaccination
As herd protection has been demonstrated after imple-
mentation of pertussis vaccination in children [37;38], 
it seems reasonable to assume that vaccination of 
adults can lead to reduction of disease in unprotected 
individuals, particularly infants. Furthermore, a model-
ling study has estimated that around 34% of all trans-
mission of pertussis to infants occurs via less close 
contacts [39]. Both natural and vaccine-induced immu-
nity is not lifelong [40], waning immunity in the face of 
decreased natural boosting in conjunction with increas-
ing vaccination coverage in children [41] – is likely the 
most important factor leading to high disease burden 
in adults. The aim of the addition of a pertussis booster 
to the adult vaccination schedule is thus to reduce the 
overall pertussis disease burden. The implementa-
tion of the changes to the adult pertussis vaccination 
schedule will be evaluated in regular population-based 
telephone interviews soliciting data on vaccination sta-
tus, and through analysis of routine surveillance data 
available from the former East German states, hospi-
tal discharge statistics and the established laboratory 
surveillance of molecular genetic characteristics of B. 
Pertussis.
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